And for the full year, we now expect sales to be up between 9.5% and 10%, an increase from our prior guide of 8% to 9%, and we now expect full year non-GAAP earnings per share between $8.88 and $8.98 per share, up from our prior guidance of $8.70 to $8.80 per share.
We expect Q3 sales to be approximately up 10% with non-GAAP earnings per share between $2.09 and $2.14 per share.
And for the full year, we now expect sales to be up between 9.5% and 10%, an increase from our prior guide of 8% to 9%, and we now expect full year non-GAAP earnings per share between $8.88 and $8.98 per share, up from our prior guidance of $8.70 to $8.80 per share.
Some notable Q2 wins in this segment include, an $18 million French MOI body-worn camera frame agreement, a $15 million license plate recognition software extension with US based customer, a $10 million P25 multiyear services extension for Ohio's statewide network, and a $10 million P25 maintenance renewal with the US federal customer.
We expect Q3 sales to be approximately up 10% with non-GAAP earnings per share between $2.09 and $2.14 per share.
And for the full year, we now expect sales to be up between 9.5% and 10%, an increase from our prior guide of 8% to 9%, and we now expect full year non-GAAP earnings per share between $8.88 and $8.98 per share, up from our prior guidance of $8.70 to $8.80 per share.
And finally, based on the strong backlog and momentum that we're seeing across our business, we're raising again our full year guidance for both sales and earnings per share.
GAAP earnings per share of $1.69 compared to $0.78 in the year ago quarter.
Non-GAAP earnings per share of $2.07 compared to $1.39 last year, primarily due to higher sales and improved operating leverage in both segments.
Additionally, we expanded operating margins by 220 basis points and ended the quarter with $11.2 billion of backlog, up 7% versus last year and a record for Q2.
We saw strong growth in EMEA during the quarter, while in Asia Pac growth was minimal as the region continues to navigate impacts from COVID-19.
